Cancer immunoediting from immune surveillance to immune escape
暂无分享,去创建一个
K. Tanabe | R. Kim | M. Emi | Ryungsa Kim | Kazuaki Tanabe | Manabu Emi
[1] K. Arihiro,et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. , 2006, Cancer research.
[2] M. Karin. Nuclear factor-κB in cancer development and progression , 2006, Nature.
[3] T. Tomasi,et al. Epigenetic regulation of immune escape genes in cancer , 2006, Cancer Immunology, Immunotherapy.
[4] H. Salih,et al. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA , 2006, Cancer Immunology, Immunotherapy.
[5] R. Zarbo,et al. Use of microsatellite analysis in detection of tumor lineage as a cause of death in a liver transplant patient. , 2006, Archives of pathology & laboratory medicine.
[6] G. Trinchieri,et al. Dendritic cell-NK cell cross-talk: regulation and physiopathology. , 2006, Current topics in microbiology and immunology.
[7] M. Karin. Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.
[8] C. Mignogna,et al. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? , 2006, International journal of immunopathology and pharmacology.
[9] E. Bloemena,et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients , 2006, Cancer Immunology, Immunotherapy.
[10] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[11] P. Sinha,et al. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. , 2005, Cancer research.
[12] Hua Yu,et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.
[13] B. Chauffert,et al. Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation , 2005, The Journal of experimental medicine.
[14] H. Dressman,et al. Gene Expression Changes and Signaling Events Associated with the Direct Antimelanoma Effect of IFN-γ , 2005 .
[15] M. Kloor,et al. Transmission of donor-derived small-cell carcinoma cells by a nontumor-bearing allograft. , 2005, Transplantation.
[16] G. Semenza,et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.
[17] G. Klein,et al. Surveillance against tumors--is it mainly immunological? , 2005, Immunology letters.
[18] R. Schreiber,et al. A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.
[19] K. Tanabe,et al. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses , 2005, Cancer biology & therapy.
[20] T. Soussi,et al. p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.
[21] G. Parmiani,et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. , 2005, Gastroenterology.
[22] L. de Leval,et al. Transmission of an undiagnosed sarcoma to recipients of kidney and liver grafts procured in a non‐heart beating donor , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[23] P. Sinha,et al. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression , 2005, Cancer Immunology, Immunotherapy.
[24] T. Iwakuma,et al. Li-Fraumeni Syndrome: a p53 Family Affair , 2005, Cell cycle.
[25] T. Lehnert,et al. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease , 2005, Gut.
[26] M. Mandal,et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 , 2005, Molecular Cancer Therapeutics.
[27] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[28] Simon C Watkins,et al. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] G. Trinchieri,et al. Production of type I interferons: plasmacytoid dendritic cells and beyond , 2005 .
[30] B. Erdoğan,et al. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients. , 2005, Tuberkuloz ve toraks.
[31] H. Dressman,et al. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. , 2005, Cancer research.
[32] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[33] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[34] D. Meek,et al. The p53 response to DNA damage. , 2004, DNA repair.
[35] K. Tanabe,et al. The role of Fas ligand and transforming growth factor β in tumor progression , 2004 .
[36] H. Goldschmidt,et al. Malignancy in renal transplantation. , 2004, Journal of the American Society of Nephrology : JASN.
[37] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[38] M. Smyth,et al. Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.
[39] D. Amadori,et al. Immunosuppression in Renal Cancer: Differential Expression of Signal Transduction Molecules in Tumor-Infiltrating, Near-Tumor Tissue, and Peripheral Blood Lymphocytes , 2004, Cancer investigation.
[40] K. Malmberg. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? , 2004, Cancer immunology, immunotherapy : CII.
[41] K. Tanabe,et al. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. , 2004, Cancer.
[42] Hua Yu,et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.
[43] M. Doubrovin,et al. Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma 1 , 2003, The Journal of Immunology.
[44] James E. Evans,et al. Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.
[45] R. Dummer,et al. HLA-G and IL-10 expression in human cancer--different stories with the same message. , 2003, Seminars in cancer biology.
[46] M. Miyazaki,et al. Preoperative Natural Killer Cell Activity as a Prognostic Factor for Distant Metastasis following Surgery for Colon Cancer , 2003, Digestive Surgery.
[47] G. Forni,et al. α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[48] H. Pircher,et al. A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells , 2003 .
[49] F. Balkwill,et al. IFN-γ Induces Apoptosis in Ovarian Cancer Cells in Vivo and in Vitro , 2003 .
[50] H. Joensuu,et al. Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphoma , 2003, Cancer.
[51] H. Groux,et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. , 2003, Immunity.
[52] Austin C. Stonebraker,et al. Presentation of Antigen by Endothelial Cells and Chemoattraction Are Required for Homing of Insulin-specific CD8+ T Cells , 2003, The Journal of experimental medicine.
[53] R. MacKie,et al. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. , 2003, The New England journal of medicine.
[54] J. Shabanowitz,et al. Hsp90 binds CpG oligonucleotides directly: implications for Hsp90 as a missing link in CpG signaling and recognition , 2003, Cellular and Molecular Life Sciences CMLS.
[55] F. Balkwill,et al. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] H. Pircher,et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. , 2003, Cancer research.
[57] M. Nishimura,et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.
[58] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[59] C. Yee,et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.
[60] A. Enk,et al. Immature, but not inactive: the tolerogenic function of immature dendritic cells , 2002, Immunology and cell biology.
[61] S. Akira,et al. Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation. , 2002, International immunology.
[62] D. Keskin,et al. Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.
[63] J. Sherratt,et al. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology. , 2002, Mathematical biosciences.
[64] W. Marks,et al. Transplant tumor registry: donor related malignancies , 2002, Transplantation.
[65] J. Trapani,et al. Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.
[66] Lloyd J. Old,et al. The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .
[67] K. Hiroshima,et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. , 2002, Lung cancer.
[68] Hiroaki Ikeda,et al. The roles of IFN gamma in protection against tumor development and cancer immunoediting. , 2002, Cytokine & growth factor reviews.
[69] S. Coca,et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.
[70] T. Lehnert,et al. Malignancy after renal transplantation. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[71] R. Vile. Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. , 2001 .
[72] T. Taniguchi,et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β , 2001, European journal of immunology.
[73] Adelheid Cerwenka,et al. Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.
[74] A. Hayday,et al. Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.
[75] U. Heemann,et al. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer , 2001, British Journal of Cancer.
[76] T. Eberlein,et al. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. , 2001, Surgery.
[77] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[78] J. Trapani,et al. A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.
[79] C. Heldin,et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.
[80] O. Finn,et al. Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[81] H. Kalthoff,et al. Systemic and local immunosuppression in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[82] T. Grogan,et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. , 2001, Blood.
[83] H. Schreiber,et al. Role of TGF‐β in immune‐evasion of cancer , 2001 .
[84] H. Schreiber,et al. Role of TGF-beta in immune-evasion of cancer. , 2001, Microscopy research and technique.
[85] A. Hayday,et al. Regulation of cutaneous malignancy by gammadelta T cells. , 2001, Science.
[86] M. Smyth,et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.
[87] M. Smyth,et al. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.
[88] M. Smyth,et al. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.
[89] Y. Tabira,et al. Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma. , 2000, The Annals of thoracic surgery.
[90] J. Trapani,et al. Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.
[91] T. Blankenstein,et al. CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.
[92] T. Whiteside,et al. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. , 2000, Blood.
[93] J. Trapani,et al. Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.
[94] S. Natsugoe,et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.
[95] M. Lotze,et al. IFN-α-Expressing Tumor Cells Enhance Generation and Promote Survival of Tumor-Specific CTLs , 2000, The Journal of Immunology.
[96] H. Kolb,et al. Cutting Edge: Heat Shock Protein 60 Is a Putative Endogenous Ligand of the Toll-Like Receptor-4 Complex1 , 2000, The Journal of Immunology.
[97] M. Lotze,et al. IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. , 2000, Journal of immunology.
[98] X. He,et al. Prostaglandin E2 selectively inhibits human CD4+ T cells secreting low amounts of both IL-2 and IL-4. , 1999, Journal of immunology.
[99] T. Whiteside,et al. Caspase-mediated Degradation of T-Cell Receptor z-Chain1 , 1999 .
[100] P. Klenerman,et al. Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[101] T. Whiteside,et al. Caspase-mediated degradation of T-cell receptor zeta-chain. , 1999, Cancer research.
[102] D. Carbone,et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.
[103] R. Day,et al. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. , 1998, Cancer research.
[104] C. Copie-Bergman,et al. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. , 1998, The Journal of clinical investigation.
[105] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[106] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[107] J. Sprent,et al. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.
[108] D. Carbone,et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.
[109] R. Schreiber,et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[110] B. Bonavida,et al. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent , 1997, Cancer Immunology, Immunotherapy.
[111] I. Svane,et al. MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice , 1997, Scandinavian journal of immunology.
[112] R. Zinkernagel,et al. Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.
[113] H. Ljunggren,et al. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice , 1996, European journal of immunology.
[114] I. Svane,et al. Methylcholanthrene‐induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[115] B. Griffith,et al. Solid tumors after heart transplantation: lethality of lung cancer. , 1995, The Annals of thoracic surgery.
[116] D. Taub,et al. Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .
[117] Eero Pukkala,et al. Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.
[118] R. Schreiber,et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.
[119] P. Matzinger. Tolerance, danger, and the extended family. , 1994, Annual review of immunology.
[120] G. Sakamoto,et al. Time dependency of the influence of prognostic factors on relapse in breast cancer , 1993, Cancer.
[121] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[122] V. Stewart,et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.
[123] F. Belardelli,et al. Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice , 1988, The Journal of experimental medicine.
[124] R. Wattiaux,et al. Subcellular localization of transglutaminase. Effect of collagen. , 1988, The Biochemical journal.
[125] E. Coccia,et al. Molecular mechanisms of action of interferons in the Friend virus-induced leukemia cell system. , 1987, Haematologica.
[126] R. Herberman,et al. Lymphocyte-mediated cytotoxicity. , 1987, Pediatric annals.
[127] L. Sherman,et al. The composition of the T cell receptor repertoire in nude mice. , 1987, Journal of immunology.
[128] S. Ikehara,et al. Functional T cells in athymic nude mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[129] L. Thomas. On immunosurveillance in human cancer. , 1982, The Yale journal of biology and medicine.
[130] R. Herberman,et al. Natural cell-mediated immunity. , 1978, Advances in cancer research.
[131] G. Klein. Immune surveillance--a powerful mechanism with a limited range. , 1976, National Cancer Institute monograph.
[132] J. Rygaard,et al. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. , 2009, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.
[133] O. Stutman. Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice , 1974, Science.
[134] I. Gresser,et al. Interferon and cell division. IX. Interferon-resistant L1210 cells: characteristics and origin. , 1974, Journal of the National Cancer Institute.
[135] F. Burnet. Immunological Surveillance in Neoplasia , 1971, Transplantation reviews.
[136] Old Lj,et al. Immunology of Experimental Tumors , 1964 .
[137] L. Old,et al. IMMUNOLOGY OF EXPERIMENTAL TUMORS. , 1964, Annual review of medicine.
[138] R. Prehn,et al. Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.
[139] M BURNET,et al. Cancer—A Biological Approach* , 1957, British medical journal.
[140] M. Burnet. Cancer—A Biological Approach , 1957, British medical journal.
[141] E. Wills. Enzyme inhibition by suramin and the measurement of the isoelectric points of some enzymes. , 1952, The Biochemical journal.
[142] S. Jasko,et al. Therapy , 1881, The American journal of dental science.